DK2073789T3 - Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf - Google Patents

Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf Download PDF

Info

Publication number
DK2073789T3
DK2073789T3 DK07870768.4T DK07870768T DK2073789T3 DK 2073789 T3 DK2073789 T3 DK 2073789T3 DK 07870768 T DK07870768 T DK 07870768T DK 2073789 T3 DK2073789 T3 DK 2073789T3
Authority
DK
Denmark
Prior art keywords
stable composition
bone anabolic
pthrp analogue
anabolic protein
protein
Prior art date
Application number
DK07870768.4T
Other languages
English (en)
Inventor
Michael J Dey
Nathalie Mondoly
Benedicte Rigaud
Bart Henderson
C Richard Lyttle
Original Assignee
Radius Health Inc
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2073789(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Health Inc, Ipsen Pharma Sas filed Critical Radius Health Inc
Application granted granted Critical
Publication of DK2073789T3 publication Critical patent/DK2073789T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK07870768.4T 2006-10-03 2007-10-03 Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf DK2073789T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896006P 2006-10-03 2006-10-03
PCT/US2007/021216 WO2008063279A2 (en) 2006-10-03 2007-10-03 A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof

Publications (1)

Publication Number Publication Date
DK2073789T3 true DK2073789T3 (da) 2019-08-05

Family

ID=39430237

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15176548.4T DK2957278T3 (da) 2006-10-03 2007-10-03 Stabil sammensætning omfattende pthrp og anvendelser deraf
DK07870768.4T DK2073789T3 (da) 2006-10-03 2007-10-03 Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15176548.4T DK2957278T3 (da) 2006-10-03 2007-10-03 Stabil sammensætning omfattende pthrp og anvendelser deraf

Country Status (28)

Country Link
US (1) US8148333B2 (da)
EP (2) EP2957278B1 (da)
JP (1) JP5375611B2 (da)
KR (4) KR20170067906A (da)
CN (2) CN101578093B (da)
AU (1) AU2007322334B2 (da)
BR (2) BRPI0719821B8 (da)
CA (1) CA2664734C (da)
CY (1) CY1119198T1 (da)
DK (2) DK2957278T3 (da)
ES (2) ES2637283T3 (da)
FR (1) FR23C1024I2 (da)
HR (1) HRP20171217T1 (da)
IL (1) IL197926A (da)
LT (1) LT2957278T (da)
LU (1) LUC00309I2 (da)
MX (1) MX2009003569A (da)
NL (1) NL301235I2 (da)
NO (1) NO344885B1 (da)
NZ (1) NZ576682A (da)
PL (1) PL2957278T3 (da)
PT (2) PT2073789T (da)
RS (1) RS56164B1 (da)
RU (1) RU2506070C2 (da)
SG (1) SG175580A1 (da)
SI (1) SI2957278T1 (da)
UA (1) UA98776C2 (da)
WO (1) WO2008063279A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
EP2472329B1 (en) 2010-12-31 2013-06-05 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2472328B1 (en) 2010-12-31 2013-06-19 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2699252B1 (en) 2011-04-22 2017-10-25 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
KR20150116467A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
KR102143482B1 (ko) * 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
CA2977812A1 (en) * 2015-03-03 2016-09-09 Radius Health, Inc. Uses of pthrp analogue in reducing fracture risk
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
CN108025042A (zh) * 2015-07-06 2018-05-11 董正欣 PTHrP类似物的新型制剂
CN106479329A (zh) 2015-08-31 2017-03-08 罗门哈斯电子材料有限责任公司 与外涂布光致抗蚀剂一起使用的涂料组合物
KR20180067573A (ko) * 2015-10-09 2018-06-20 라디우스 헬쓰, 인코포레이티드 PTHrP 유사체의 제형, 이의 경피 패취, 및 이의 용도
US10568937B2 (en) 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
CN1204262A (zh) * 1995-10-17 1999-01-06 曼海姆泊灵格股份公司 稳定的含甲状旁腺激素的药物给药剂型
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
HRP20000109A2 (en) 1997-09-09 2001-02-28 Hoffmann La Roche FRACTURE HEALING USING PTHrP ANALOGS
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7799757B2 (en) * 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
CA2511966A1 (en) 2002-11-01 2004-07-22 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes

Also Published As

Publication number Publication date
DK2957278T3 (da) 2017-07-31
CA2664734A1 (en) 2008-05-29
PT2073789T (pt) 2019-07-31
AU2007322334B2 (en) 2011-12-22
CA2664734C (en) 2023-08-01
EP2957278B1 (en) 2017-05-17
FR23C1024I1 (fr) 2023-07-21
WO2008063279A9 (en) 2008-07-10
BRPI0719821B8 (pt) 2021-05-25
UA98776C2 (ru) 2012-06-25
NO20091545L (no) 2009-05-27
LT2957278T (lt) 2017-09-11
KR20090083350A (ko) 2009-08-03
KR20180117738A (ko) 2018-10-29
PL2957278T3 (pl) 2017-10-31
NO344885B1 (no) 2020-06-15
CN102274492B (zh) 2014-11-26
CY1119198T1 (el) 2018-02-14
ES2739459T3 (es) 2020-01-31
KR20150020289A (ko) 2015-02-25
KR20170067906A (ko) 2017-06-16
RS56164B1 (sr) 2017-11-30
HRP20171217T1 (hr) 2017-10-20
NZ576682A (en) 2012-08-31
RU2506070C2 (ru) 2014-02-10
SI2957278T1 (sl) 2017-09-29
WO2008063279A3 (en) 2009-06-25
BRPI0719821B1 (pt) 2020-04-14
EP2073789A2 (en) 2009-07-01
NL301235I2 (nl) 2023-08-31
SG175580A1 (en) 2011-11-28
CN101578093A (zh) 2009-11-11
IL197926A (en) 2014-08-31
IL197926A0 (en) 2011-08-01
EP2957278A1 (en) 2015-12-23
LUC00309I2 (da) 2025-09-22
US20100029556A1 (en) 2010-02-04
HK1214181A1 (en) 2016-07-22
EP2073789B1 (en) 2019-05-22
BRPI0722428A2 (pt) 2013-11-26
JP5375611B2 (ja) 2013-12-25
KR101512377B1 (ko) 2015-04-28
CN102274492A (zh) 2011-12-14
FR23C1024I2 (fr) 2024-06-14
RU2009116531A (ru) 2010-11-10
CN101578093B (zh) 2011-09-14
ES2637283T3 (es) 2017-10-11
MX2009003569A (es) 2009-08-25
AU2007322334A1 (en) 2008-05-29
EP2073789B8 (en) 2023-02-08
BRPI0719821A2 (pt) 2013-05-07
WO2008063279A2 (en) 2008-05-29
US8148333B2 (en) 2012-04-03
PT2957278T (pt) 2017-08-23
JP2010505835A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
DK2073789T3 (da) Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf
PL1888031T3 (pl) Preparaty analogu glp-1
IL192104A0 (en) Stable protein formulations
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IL194638A0 (en) Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
LTC2091918I2 (lt) Junginiai ir kompozicijos, kaip proteinkinazės inhibitoriai
IL199397A (en) Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
ZA200906699B (en) Insecticidal proteins
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
IL217841A0 (en) Long lasting drug formulations
DK1928409T3 (da) Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid
IL187534A0 (en) Thiazole derivatives, use thereof and pharmaceutical compositions containing them
IL186258A0 (en) Chimeric proteins, their preparation and pharmaceutical compositions containing them
ZA200900237B (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
IL187339A0 (en) Pharmaceutical formulations for minimizing drug-drug interactions
IL192149A0 (en) Stable s-nitrosothiol formulations
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
IL184631A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A Wht3a PROTEIN
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
ZA200808769B (en) Pharmaceutical compostion containing the NMB0938 protein
IL190926A0 (en) A pharmaceutical composition containing a tissue protein
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative